Notably, therapeutic strategies targeting the XBP1/cholesterol axis or reducing cholesterol levels in tumors decrease MDSC abundance and reinstate robust antitumor responses, underscoring the potential of this pathway as a target to improve cancer immunotherapy outcomes [112]. The gene discussed is XBP1; the disease is cancer.